Interv Akut Kardiol. 2020;19(3):182-183 | DOI: 10.36290/kar.2020.040

Kontroverze - aspirin po PCI?Aspirin po PCI: proč nepodávat

Ivo Varvařovský
Kardiologické centrum Agel, Pardubice

Published: September 2, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Varvařovský I. Kontroverze - aspirin po PCI?Aspirin po PCI: proč nepodávat. Interv Akut Kardiol. 2020;19(3):182-183. doi: 10.36290/kar.2020.040.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Am J Med 2008; 121: 43-49. Go to original source... Go to PubMed...
    2. Antiplatelet Trialists´ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. BMJ 1994; 308: 81-106. Go to original source... Go to PubMed...
    3. Kenaan M, Seth M, Aronow HD. The clinical outcomes of percutaneous coronary intervention performed without pre-procedural aspirin. J Am Coll Cardiol 2013; 62: 2083-2089. Go to original source...
    4. Neumann FJ, Sousa-Uva M, Ahlsson A. 2018 ESC/EACTS guidelines on myocardial revascularization. European Heart Journal 2019; 40: 87-165. Go to original source...
    5. Vranckx P, Valgimigli M, Jűni P. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel for 12 months followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet 2018; 392: 940-949. Go to original source...
    6. Watanabe H. One-month dual antiplatelet therapy followed by clopidogrel monotherapy versus standard 12-month dual antiplatelet therapy with clopidogrel after drug-eluting stent implantation: STOPDAPT-2 trial. Presented at: ACC 2019. March 18, 2019. New Orleans, LA.
    7. Hahn J-Y. P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized, open-label, noninferiority trial. Presented at: ACC 2019. March 18, 2019. New Orleans, LA. Go to original source...
    8. Dewilde WJ, Oirbans T, Verheugt FW. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013; 381: 1107-1115. Go to original source...
    9. Gibson CM, Mehran R, Bode C. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016; 375: 2423-2434. Go to original source...
    10. Cannon CP, Bhatt DL, Oldgren J. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017; 377: 1513-1524. Go to original source...
    11. Lopes RD, Heizer G, Aronson R. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 2019; 380: 1509-1524. Go to original source...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.